Clinical Infectious Diseases,
Год журнала:
2024,
Номер
79(2), С. 395 - 404
Опубликована: Март 11, 2024
Abstract
Background
We
aimed
to
determine
if
pre-existing
immunocompromising
conditions
(ICCs)
were
associated
with
the
presentation
or
outcome
of
patients
acute
coronavirus
disease
2019
(COVID-19)
admitted
for
pediatric
intensive
care.
Methods
Fifty-five
hospitals
in
30
US
states
reported
cases
through
Overcoming
COVID-19
public
health
surveillance
registry.
Patients
<21
years
12
March
2020–30
December
2021
care
unit
(PICU)
high-acuity
included.
Results
Of
1274
patients,
105
(8.2%)
had
an
ICC,
including
33
(31.4%)
hematologic
malignancies,
24
(22.9%)
primary
immunodeficiencies
and
disorders
hematopoietic
cells,
19
(18.1%)
nonmalignant
organ
failure
solid-organ
transplantation,
16
(15.2%)
solid
tumors,
13
(12.4%)
autoimmune
disorders.
ICCs
older,
more
underlying
renal
conditions,
lower
white
blood
cell
platelet
counts
than
those
without
ICCs,
but
similar
clinical
severity
upon
admission.
In-hospital
mortality
from
was
higher
(11.4%
vs
4.6%,
P
=
.005)
hospitalization
longer
(P
.01)
ICCs.
New
major
morbidities
discharge
not
different
between
ICC
(10.5%
13.9%,
.40).
In
bacterial
coinfection
common
life-threatening
COVID-19.
Conclusions
this
national
case
series
age
care,
existence
a
prior
worse
outcomes.
Reassuringly,
most
hospitalized
PICU
severe
survived
discharged
home
new
morbidities.
COVID-19,
the
coronavirus
disease
that
emerged
in
December
2019,
caused
drastic
damage
worldwide.
At
beginning
of
pandemic,
available
data
suggested
infection
occurs
more
frequently
adults
than
infants.
In
this
review,
we
aim
to
provide
an
overview
SARS-CoV-2
children
before
and
after
B.1.617.2
Delta
B.1.1.529
Omicron
variants
emergence
terms
prevalence,
transmission
dynamics,
clinical
manifestations,
complications
risk
factors.
Clinical & Experimental Immunology,
Год журнала:
2022,
Номер
209(3), С. 247 - 258
Опубликована: Янв. 28, 2022
Abstract
In
March
2020,
the
United
Kingdom
Primary
Immunodeficiency
Network
(UKPIN)
established
a
registry
of
cases
to
collate
outcomes
individuals
with
PID
and
SID
following
SARS-CoV-2
infection
treatment.
A
total
310
in
or
have
now
been
reported
UK.
The
overall
mortality
within
cohort
was
17.7%
(n
=
55/310).
Individuals
CVID
demonstrated
an
fatality
rate
(IFR)
18.3%
17/93),
receiving
IgRT
had
IFR
16.3%
26/159)
SID,
27.2%
25/92).
higher
inpatient
died
at
younger
age
than
general
population.
Increasing
age,
low
pre-SARS-CoV-2
lymphocyte
count
presence
common
co-morbidities
increased
risk
PID.
Access
specific
COVID-19
treatments
this
limited:
only
22.9%
33/144)
patients
admitted
hospital
received
dexamethasone,
remdesivir,
anti-SARS-CoV-2
antibody-based
therapeutic
(e.g.
REGN-COV2
convalescent
plasma)
tocilizumab
as
monotherapy
combination.
Dexamethasone,
therapeutics
appeared
efficacious
SID.
Compared
population,
are
high
infection.
baseline
count,
additional
factors
for
poor
outcome
cohort.
Journal of Clinical Investigation,
Год журнала:
2022,
Номер
132(12)
Опубликована: Май 10, 2022
BACKGROUNDPatients
undergoing
immune-modifying
therapies
demonstrate
a
reduced
humoral
response
after
COVID-19
vaccination,
but
we
lack
proper
evaluation
of
the
effect
such
on
vaccine-induced
T
cell
responses.METHODSWe
longitudinally
characterized
and
spike-specific
responses
in
patients
with
inflammatory
bowel
disease
(IBD),
who
were
antimetabolite
therapy
(azathioprine
or
methotrexate),
TNF
inhibitors,
and/or
other
biologic
treatment
(anti-integrin
anti-p40)
for
up
to
6
months
completing
2-dose
mRNA
vaccination.RESULTSWe
that
was
not
only
induced
treated
IBD
at
levels
similar
those
healthy
individuals,
also
sustained
higher
magnitude
particularly
inhibitor
therapy.
Furthermore,
these
mainly
preserved
against
mutations
present
SARS-CoV-2
B.1.1.529
(Omicron)
by
Th1/IL-10
cytokine
profile.CONCLUSIONDespite
defects,
under
demonstrated
favorable
profile
might
still
provide
layer
protection.FUNDINGThis
study
funded
National
Centre
Infectious
Diseases
(NCID)
Catalyst
Grant
(FY2021ES)
Research
Fund
Competitive
Programme
(NRF-CRP25-2020-0003).
The Journal of Infectious Diseases,
Год журнала:
2023,
Номер
228(Supplement_1), С. S24 - S33
Опубликована: Май 24, 2023
Primary
immunodeficiencies
(PIDs)
are
heterogeneous,
rare
disorders
that
increase
susceptibility
to
infection
and/or
immune
dysregulation.
Individuals
with
certain
PIDs
at
high
risk
of
severe
or
fatal
outcomes
from
SARS-CoV-2
infections
(the
causative
agent
COVID-19),
either
due
the
underlying
PID
presence
comorbidities
such
as
lung
and
liver
disease.
Vaccination
remains
primary
strategy
protect
individuals
COVID-19.
However,
populations
exhibit
variable
vaccine
seroresponse
rates,
antibody
titers,
neutralization
activity
depending
on
type
COVID-19
vaccine,
consequently,
an
elevated
In
this
article,
we
review
burden
in
patients
focus
in-depth
findings
predominantly
deficiencies
combined
immunodeficiencies.
We
conclude
by
providing
vaccination
recommendations
for
population.
Abstract
Background
Primary
Immunodeficiency
disorders
(PID)
can
increase
the
risk
of
severe
COVID-19
and
prolonged
infection.
This
study
investigates
duration
SARS-CoV-2
excretion
genetic
evolution
virus
in
pediatric
PID
patients
as
compared
to
immunocompetent
(IC)
patients.
Materials
methods
A
total
40
nasopharyngeal
24
stool
samples
were
obtained
from
five
ten
IC
children.
RNA
detection
was
performed
using
RT-qPCR,
whole-genome
sequencing
conducted
with
NexSeq
1000
platform.
Data
analysis
used
nextflow/viralrecon
pipeline.
Hotspot
amino
acid
frequencies
investigated
GraphPad
Prism
v10.
Phylodynamic
BEAST
software.
Results
In
children,
viral
period
lasted
up
14
days
swabs,
an
average
7
days,
ranged
samples.
patients,
detected
for
periods
between
28
15
Two
variants
patients:
Delta
(AY.122)
Omicron
(BA.1.1).
Patients
antibody
combined
deficiencies,
exhibited
most
shedding
both
one
patient
presented
complications
fatal
outcome.
Specific
changes
PID:
A2821V
R550H
(ORF1ab).
Conclusion
Our
findings
underscore
deficiencies.
Thus,
specialized
care
is
essential
effectively
managing
Frontiers in Immunology,
Год журнала:
2023,
Номер
14
Опубликована: Авг. 25, 2023
Background
Despite
children
and
young
people
(CYP)
having
a
low
risk
for
severe
coronavirus
disease
2019
(COVID-19)
outcomes,
there
is
still
degree
of
uncertainty
related
to
their
in
the
context
immunodeficiency
or
immunosuppression,
primarily
due
significant
reporting
bias
most
studies,
as
CYP
characteristically
experience
milder
asymptomatic
COVID-19
infection
outcomes
tend
be
overestimated.
Methods
A
comprehensive
systematic
review
identify
globally
relevant
studies
immunosuppressed
general
population
(defined
younger
than
25
years
age)
up
31
October
2021
(to
exclude
vaccinated
populations)
was
performed.
Studies
were
included
if
they
reported
two
primary
our
study,
admission
intensive
therapy
unit
(ITU)
mortality,
while
data
on
other
such
hospitalization
need
mechanical
ventilation
also
collected.
meta-analysis
estimated
pooled
proportion
each
outcome,
using
inverse
variance
method.
Random
effects
models
used
account
interstudy
heterogeneity.
Findings
The
identified
30
eligible
populations
investigated:
(
n
=
793)
102,022).
Our
found
higher
prevalence
(46%
vs.
16%),
ITU
(12%
2%),
(8%
1%),
increased
mortality
(6.5%
0.2%)
immunocompromised
compared
with
population.
This
shows
an
overall
trend
more
CYP,
similar
adult
studies.
Interpretation
only
up-to-date
high
global
relevance,
which
excluded
reports
from
hospitalized
cohorts
alone
35%
low-
middle-income
countries.
Future
research
required
characterize
individual
subgroups
patients,
well
impact
vaccination
outcomes.
Systematic
Review
Registration
PROSPERO
identifier,
CRD42021278598.
